Oisin Biotechnologies

Executive Summary

Oisin Biotechnologies is a Seattle-based private biotech company founded in 2015, developing genetic medicines to address age-related diseases. Its core technology, Fusogenix™ Proteo-Lipid Vehicle (PLV), is a non-viral delivery platform designed for safe, repeated dosing of DNA and RNA payloads with extensive extrahepatic biodistribution. The company targets multiple aging drivers including frailty, fat accumulation, and cellular senescence. While still in preclinical or early clinical stages, Oisin's platform holds potential to differentiate from viral vectors by enabling re-dosing and broader tissue targeting. The company has not disclosed significant funding rounds or partnerships yet, but recent progress in the age-related disease space and growing interest in non-viral delivery could position it for future milestones.

Upcoming Catalysts (preview)

• Q2 2026Lead Program IND Filing30% success
• Q4 2026Series A Funding Announcement50% success
• Q3 2026New Preclinical Data Presentation70% success